The 22 references in paper E. Sokova A., I. Mazerkina A., O. Demidova A., T. Aleksandrova V., Е. Сокова А., И. Мазеркина А., О. Демидова А., Т. Александрова В. (2018) “Особенности клинической фармакологии лекарственных средств, применяемых для фармакотерапии ВИЧ-инфекции во время беременности // Clinical pharmacology aspects of drugs for hiv-infected pregnant women” / spz:neicon:vedomostincesmp:y:2017:i:3:p:150-154

1
Darak S, Parchure R, Darak T, Talavlikar R, Kulkarni S, Kulkarni V. Advances in the prevention of mother-to-child transmission of HIV and resulting clinical and programmatic implications. Research and Reports in Neonatology 2014; 4: 111–23.
(check this in PDF content)
2
Roustit M, Jlaiel M, Leclercq P, Stanke-Labesque F. Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. Br J Clin Pharmacol. 2008; 66(2): 179–95.
(check this in PDF content)
3
Sokova EA, Chilova RA, Proklova GF, Meksha YuV, Demidova OA. The characteristics of drug metabolism during pregnancy. The Bulletin ofContemporary Clinical Medicine 2016; 9(5): 70–5 (in Russian).
(check this in PDF content)
4
Mattison DR. Clinical pharmacology during pregnancy. Amsterdam: Elsevier; 2013.
(check this in PDF content)
5
Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services [Internet]. 2016 [cited 2017 Jul 10]. Available from: https://goo.gl/ RpJPfc.
(check this in PDF content)
6
Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of antiretroviral therapy in early asymptomatic HIV Infection. ¹ Engl J Med. 2015; 373(9): 795–807.
(check this in PDF content)
7
Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States [Internet]. 2016 [cited 2017 Jul 10]. Available from: https:// goo.gl/5VKzKy.
(check this in PDF content)
8
Zhuravleva EO, Velts NYu, Zatolochina KE, Glagolev SV, Polivanov VA, Darmostukova MA, et al. Analysis of spontaneous reports of adverse reactions, developed in the use of drugs during pregnancy.Safety and Risk of Pharmacotherapy 2017; 5(2): 61–69 (in Russian).
(check this in PDF content)
9
The use of antiretroviral drugs as part of a set of measures aimed at preventing the transmission of HIV from mother to child. Clinical recommendations (protocol of treatment) of the Ministry of Health of the Russian Federation. Available from: http://minzdrav.midural.ru/uploads/1120%D0%B0.pdf (in Russian).
(check this in PDF content)
10
Schaefer C, Spielmann H, Vetter K. Drug therapy during pregnancy and lactation. Moscow: Logosfera; 2010 (in Russian).
(check this in PDF content)
11
Best B, Stek A, Hu C, Burchett SK, Rossi SS, Smith E, et al. High-dose Lopinavir and standard dose emtricitabine pharmacokinetics during pregnancy and postpartum. 15th Conference on Retroviruses and Opportunistic Infections, February 3–6, 2008, Boston, MA, USA.
(check this in PDF content)
12
Capparelli EV, Aweeka F, Hitti J, Stek A, Hu C, Burchett SK, et al. Chronic administration of Nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Med. 2008; 9(4): 214–20.
(check this in PDF content)
13
Lugt J, Colbers A, Molto J, Hawkins D, van der Ende M, Vogel M, et al. The pharmacokinetics, safety and efficacy of boosted Saquinavir tablets in HIV type-1-infected pregnant women. Antivir Ther. 2009; 14(3): 443–50.
(check this in PDF content)
14
Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 2000; 283(9): 1175–82.
(check this in PDF content)
15
Flynn PM, Mirochnick M, Shapiro DE, Bardeguez A, Rodman J, Robbins B, et al. Pharmacokinetics and safety of single-dose Tenofovir disoproxil fumarate and Emtricitabine in HIV-1-infected pregnant women and their infants. Antimicrob Agents Chemother. 2011; 55(12): 5914–22.
(check this in PDF content)
16
Sokova EA. Monitoring post-approval drug safety in pregnancy: pharmacogenetic aspects. Safety and Risk of Pharmacotherapy 2015; (3): 30–35 (in Russian).
(check this in PDF content)
17
Gedeon C, Koren G. Designing pregnancy centered medications: drugs which do not cross the human placenta. Placenta 2006; 27(8): 861–8.
(check this in PDF content)
18
Sudhakaran S, Rayner CR, Li J, Kong DC, Gude NM, Nation RL. Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus. Br J Clin Pharmacol. 2008; 65(5): 667–73.
(check this in PDF content)
19
Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol. 2007; 73(10): 1573–81.
(check this in PDF content)
20
Minuesa G, Volk C, Molina-Arcas M, Gorboulev V, Erkizia I, Arndt P, et al. Transport of lamivudine [(-)-beta-L-2¢,3¢-dideoxy-3¢-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther. 2009; 329(1): 252–61.
(check this in PDF content)
21
Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, Haefeli WE, Efferth T. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother. 2007; 59(2): 238–45.
(check this in PDF content)
22
Gulati A, Gerk PM. Role of placental ATP-binding cassette (ABC) trasporters in antiretroviral therapy during pregnanacy. J Pharm Sci. 2009; 98(7): 2317–35. AUTHORS Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health
(check this in PDF content)